Panbela Therapeutics, INC 8-K filings

Panbela Therapeutics reduces annual compensation for its CEO and CFO, effective February 12, 2025.

Panbela Therapeutics approves retention bonuses for key employees, including the CEO and CFO, to incentivize continued employment through potential milestones or December 31, 2025.

Panbela Therapeutics reports an event of default on its convertible notes, potentially leading to increased interest rates and the lender's option to convert debt into equity.

Panbela Therapeutics has finalized a $9.15 million financing agreement with Nant Capital through the issuance of a Senior Convertible Promissory Tranche B Note.

Panbela Therapeutics announced a $12 million strategic financing from Nant Capital, along with progress in its clinical trials and third-quarter 2024 financial results.

Panbela Therapeutics has entered into a note purchase agreement for $12 million in convertible debt financing to support general corporate purposes and repay existing debt.

Panbela Therapeutics has approved retention bonuses for its CEO and CFO, contingent on continued employment and specific milestones.

Panbela Therapeutics announced a business update and financial results for the second quarter of 2024, highlighting clinical trial progress and revised timelines for data analysis.

Panbela Therapeutics, Inc. and its subsidiary, Cancer Prevention Pharmaceuticals, Inc., have entered into a loan agreement for $1.5 million to support research and working capital.

Panbela Therapeutics has eliminated its Series A Preferred Stock by filing a Certificate of Elimination with the Delaware Secretary of State, following shareholder approval of a reverse stock split.

Panbela Therapeutics' stockholders approved a reverse stock split and a proposal to adjourn the special meeting if necessary, though adjournment was not required.

Panbela Therapeutics reported its Q1 2024 financial results, highlighted by a revised timeline for its ASPIRE trial interim data analysis and a $9 million public offering.

Panbela Therapeutics issued a single share of Series A Preferred Stock for $10, initiated a delisting from Nasdaq, and applied to list on the CBOE.

Panbela Therapeutics has announced that the interim data analysis for its ASPIRE trial has been pushed to Q1 2025 due to a lower-than-expected event rate, which suggests improved patient survival.

Panbela Therapeutics will move its stock listing to the OTCQB market after failing to meet Nasdaq's minimum equity requirements.

Panbela Therapeutics announced its full year 2023 financial results and provided a business update, highlighting clinical trial progress and collaborations.

Panbela Therapeutics will be delisted from the Nasdaq Stock Market due to a failure to meet minimum stockholders' equity requirements, with trading to be suspended on March 7, 2024.

Panbela Therapeutics has successfully regained compliance with Nasdaq listing standards for bid price and publicly held shares, as confirmed by Nasdaq on February 13, 2024.

Panbela Therapeutics has approved retention bonuses for key executives and certified incentive payouts for the 2023 fiscal year, with the CEO waiving her bonus.

Panbela Therapeutics has successfully closed a public offering, raising approximately $9 million in gross proceeds.

Panbela Therapeutics has announced the pricing of a public offering expected to generate approximately $9.0 million in gross proceeds.

Panbela Therapeutics is at risk of being delisted from the Nasdaq due to non-compliance with listing rules, despite exceeding 50% enrollment in its ASPIRE clinical trial for pancreatic cancer treatment.

Panbela Therapeutics has completed a 1-for-20 reverse stock split, effective January 18, 2024, to consolidate its outstanding shares.